LimFlow SA
LimFlow SA is a medical device company that develops and commercializes the first FDA-approved system for Transcatheter Arterialization of Deep Veins (TADV) to treat no-option chronic limb-threatening ischemia (CLTI) patients facing major amputation, selling directly to hospitals and ASCs. Acquired by Inari Medical (Stryker) in November 2025.
- Company typePrivate
- Founded2014
- HeadquartersParis, France
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What LimFlow SA does
LimFlow SA is a venture-backed medical device company founded in 2014 and headquartered in Paris, France, with a U.S. operational headquarters in San Jose, California. The company developed and commercializes the LimFlow System, the first and only FDA-approved (September 2023) and CE-marked (October 2016) device for Transcatheter Arterialization of Deep Veins (TADV) — a minimally-invasive procedure designed to treat patients with chronic limb-threatening ischemia (CLTI) who have exhausted all endovascular and surgical revascularization options and face imminent major amputation. The target patient population in the U.S. alone exceeds 150,000 major amputations per year, with CLTI affecting up to 4 million Americans and disproportionately impacting minority and underserved populations.
The LimFlow System is a purpose-built, fully percutaneous family of products designed to bypass unreconstructable blocked arteries by diverting oxygenated blood through the deep veins back into the ischemic foot. The product family includes the LimFlow ARC arterial catheter (with embedded crossing needle), the V-Ceiver venous catheter (with radiopaque mesh target), the Vector push valvulotome (4Fr over-the-wire device for lysing venous valves while preserving vessel walls), proprietary tapered nitinol crossing stents with electrospun PTFE cover, and extension covered stents to maintain outflow. Clinical evidence supporting the system includes the PROMISE II pivotal trial (105 patients, 76% limb salvage at 12 months, published in the New England Journal of Medicine), PROMISE I, ALPS Registry, and First-in-Human studies, with PROMISE III ongoing.
The business model is direct enterprise sales of capital-procedure hardware to hospitals and ambulatory surgical centers, with procedures reimbursed under CPT code 0620T. Medicare established approximately $45,000 average hospital outpatient payment and approximately $39,620 in ASCs effective January 2026, plus NTAP add-on payments of up to $16,250 for inpatient cases effective October 2024. LimFlow commercialized directly in Europe following CE Mark and built a U.S. field sales organization after FDA approval, with a dedicated HEMA team supporting coding, billing, and prior authorization. As of November 2025, LimFlow was acquired by Inari Medical (now part of Stryker), operating as a subsidiary with LimFlow branding retained and leveraging Inari/Stryker's commercial infrastructure. Total disclosed funding exceeds $73.5 million across Series A (undisclosed, September 2014), Series C (€27M, April 2018, Sofinnova-led), and Series D ($40M, April 2022, Longitude/Soleus-led).
LimFlow SA firmographics
Firmographics- Name
- LimFlow SA
- Legal name
- LimFlow SA
- Website
- https://limflow.com
- Company type
- Private
- Founded year
- 2014
- Operating status
- Acquired
- Headcount range
- 11–50 employees
- Short description
- LimFlow SA is a medical device company that develops and commercializes the first FDA-approved system for Transcatheter Arterialization of Deep Veins (TADV) to treat no-option chronic limb-threatening ischemia (CLTI) patients facing major amputation, selling directly to hospitals and ASCs. Acquired by Inari Medical (Stryker) in November 2025.
- Ownership category
- akta.pro rank
LimFlow SA industry classification
Industry- Product category
- Peripheral Vascular Medical Devices
- NAICS
- Surgical and Medical Instrument Manufacturing (339112)
- SIC
- Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Thrombectomy, Embolic Protection & Stroke Intervention Devices (HLAHAFAJ)
Keywords
Where LimFlow SA is headquartered
LocationHeadquarters
- HQ city
- Paris
- HQ country
- France
- HQ region
- Europe
Offices2 records
Markets served
LimFlow SA business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Marketing or Sales, Supply Chain, Operations
Revenue model
- LimFlow System Device Sales: The company generates revenue through the sale of its LimFlow System, a family of transcatheter products including the ARC, V-Ceiver, Vector, crossing stents, and extension stents. As of FDA approval in September 2023, the company transitioned from pre-commercial (clinical trial) stage to commercial operations in the U.S. The system was previously commercially available in Europe following CE Mark approval in October 2016.
- Procedure/Reimbursement Revenue: Hospitals and ASCs bill for the LimFlow TADV procedure using CPT code 0620T. Medicare has established specific payment rates: approximately $45,000 average in hospital outpatient departments and $39,620 in ASCs (effective January 2026), plus potential NTAP add-on payments of up to $16,250 for inpatient cases.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Pay-as-you-go | Medicare Hospital Outpatient Payment (2026) |
| Other | Pay-as-you-go | Medicare ASC Payment (2026) |
| Other | Pay-as-you-go | Medicare NTAP Inpatient Add-on Payment |
Go-to-market motion2 records
Distribution channels2 records
Marketing channels6 records
LimFlow SA product offering
Product offeringCore offering
LimFlow SA develops, manufactures and commercializes the LimFlow System for Transcatheter Arterialization of Deep Veins (TADV), a fully percutaneous, minimally-invasive family of medical devices used to bypass blocked arteries in the legs of patients with end-stage Chronic Limb-Threatening Ischemia (CLTI) who have no remaining endovascular or surgical revascularization options. The system delivers oxygenated blood back into the foot via the deep veins to prevent major amputation, heal wounds and relieve pain, and is sold to hospitals and ambulatory surgical centers through direct enterprise sales.
Product overview
LimFlow SA offers the LimFlow System for Transcatheter Arterialization of Deep Veins (TADV), a comprehensive family of fully percutaneous medical devices designed to treat chronic limb-threatening ischemia (CLTI) in patients with no other revascularization options. The system consists of multiple interconnected components: the LimFlow ARC arterial catheter and V-Ceiver venous catheter for artery-to-vein crossing, the Vector valvulotome for lysing venous valves, and proprietary Crossing Stents and Extension Covered Stents to maintain the arterialized flow pathway. Together, these products restore blood flow to the ischemic foot by diverting blood around diseased arteries through the deep veins, potentially avoiding major amputation and promoting wound healing.
Differentiator
Problem solved
Functional benefit
Products and services
- LimFlow System for Transcatheter Arterialization of Deep Veins (TADV) Minimally-invasive, fully percutaneous medical device system designed to bypass blocked arteries in the leg and deliver oxygenated blood back into the foot via the deep veins, for patients with chronic limb-threatening ischemia (CLTI) who have no remaining endovascular or surgical revascularization options and are at risk of major amputation. Sold to hospitals and ambulatory surgical centers.
- LimFlow ARC Arterial Catheter (2nd Generation) Purpose-built arterial catheter that enables optimal visual alignment under fluoroscopy for artery-to-vein crossing during the LimFlow TADV procedure; features an embedded crossing needle with long reach for multiple crossing options in below-the-knee procedures. A sub-component of the LimFlow System sold as part of the integrated TADV platform.
- LimFlow V-Ceiver Venous Catheter (2nd Generation) Purpose-built venous catheter with a radiopaque mesh that fills the vein to provide a distinct visual target during artery-to-vein crossing in the LimFlow TADV procedure. Sub-component of the integrated LimFlow System.
- LimFlow Vector Valvulotome Unique 4Fr over-the-wire push valvulotome specifically designed to lyse venous valves by pushing downward from tibial to distal pedal veins, with a cutting basket featuring forward-facing hooks designed to preserve venous walls and avoid vessel trauma. Sub-component of the LimFlow System.
- LimFlow Crossing Stent System Proprietary tapered nitinol crossing stent with electrospun PTFE cover material designed to create the channel for blood to flow from artery to vein and to optimize sizing for both artery and vein to maximize flow. Sub-component of the LimFlow System.
- LimFlow Extension Covered Stents Novel electrospun PTFE-covered nitinol extension stents designed to maximize outflow to the foot by keeping valves in the calf open while blocking smaller veins from taking flow back to the heart. Sub-component of the LimFlow System.
Quantifiable outcome
- 76% limb salvage at 12 months in PROMISE II pivotal trial
- +6 more outcomes
Companies that use LimFlow SA
Customer profileNamed customers8 records
Segments3 records
Ideal customer profiles3 records
LimFlow SA technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
LimFlow SA partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Inari Medical (now part of Stryker)coreLimFlow is now part of the Inari Medical family (Inari Medical was acquired by Stryker). The company operates as a subsidiary with LimFlow branding maintained. Inari provides commercial infrastructure, health economics support, and organizational resources. Website states 'LimFlow is proud to be part of the Inari Medical family.'
Scale indicators9 records
Recent moves8 records
Expansion highlights6 records
LimFlow SA competitors and assessment
Company assessmentBroad incumbents
- Boston Scientific: Boston Scientific's peripheral intervention franchise (Eluvia drug-eluting stent, Ranger balloon, atherectomy, thrombectomy) addresses CLTI and PAD with overlapping patient populations. It is comparable as a large, diversified peripheral vascular incumbent selling to the same vascular specialist channel as LimFlow.
- Medtronic: Medtronic's peripheral vascular and cardiac surgery businesses (including drug-coated balloons, stents, and TAVR heritage of VP Commercial Ops Mike Mathias) serve the same vascular specialist call point as LimFlow. As a broad incumbent, it offers overlapping capabilities that could reduce the no-option CLTI pool.
- Terumo (Terumo Interventional Systems): Terumo's interventional systems business manufactures peripheral vascular catheters, guidewires, and stent systems used by vascular specialists. It overlaps with LimFlow in the peripheral vascular intervention device category and shares Japanese and European market presence relevant to LimFlow's international expansion plans.
- Abbott Vascular: Abbott's vascular division offers a broad portfolio of peripheral intervention devices including drug-coated balloons, stents, and atherectomy systems (via CSI acquisition). It serves the same vascular specialists and hospitals as LimFlow and could compete indirectly by keeping more patients within conventional revascularization pathways.
- Shockwave Medical (Johnson & Johnson): Shockwave pioneered intravascular lithotripsy (IVL) for calcified peripheral and coronary lesions, an alternative revascularization approach for CLTI patients. It is comparable to LimFlow as a peripheral vascular intervention company whose technology can compete for the same CLTI patient pool, and is now part of J&J's cardiovascular franchise.
- Philips (Image-Guided Therapy / Peripheral Vascular): Philips' image-guided therapy business sells peripheral vascular imaging, atherectomy, and therapeutic devices to vascular specialists and hospitals. It is comparable to LimFlow as a broad incumbent operating across the peripheral vascular intervention workflow with overlapping hospital customers.
Emerging players
- Avinger: Avinger develops catheter-based lumivascular systems for peripheral artery disease, addressing below-the-knee and femoropopliteal lesions. It overlaps with LimFlow in the peripheral vascular intervention space, though with a smaller commercial footprint and a focus on atherectomy rather than venous arterialization.
Direct peers
- Inari Medical (Stryker): Inari Medical develops catheter-based thrombectomy systems for venous thromboembolism and is now LimFlow's parent within Stryker. It is comparable as a venture-built peripheral vascular intervention company with a specialized catheter platform, similar commercial model, and the same hospital and vascular specialist customer base.
- Silk Road Medical: Silk Road Medical commercializes minimally-invasive devices (TCAR) for vascular disease with a similarly narrow, well-defined clinical indication and reliance on specialist training and reimbursement. It shares LimFlow's profile as a single-platform peripheral vascular company selling capital-light consumables through specialist channels.
- Penumbra: Penumbra develops catheter-based mechanical thrombectomy and vascular intervention devices for peripheral and neurovascular applications. It is comparable to LimFlow as a venture-built catheter-based peripheral vascular intervention company selling disposable devices to vascular specialists and hospitals.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
LimFlow SA social profiles
Digital presenceLimFlow SA compliance and trust
Trust signalCompliance2 records
LimFlow SA financial estimates
Financial estimateRevenue estimate
Valuation estimate
LimFlow SA leadership team
Management profileNumber of profiles
Profiles7 records
LimFlow SA funding detail
Funding detailFunding overview
Funding rounds2 records
Investors6 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
LimFlow SA M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about LimFlow SA
What does LimFlow SA do?
LimFlow SA develops, manufactures and commercializes the LimFlow System for Transcatheter Arterialization of Deep Veins (TADV), a fully percutaneous, minimally-invasive family of medical devices used to bypass blocked arteries in the legs of patients with end-stage Chronic Limb-Threatening Ischemia (CLTI) who have no remaining endovascular or surgical revascularization options. The system delivers oxygenated blood back into the foot via the deep veins to prevent major amputation, heal wounds and relieve pain, and is sold to hospitals and ambulatory surgical centers through direct enterprise sales.
Is LimFlow SA a public or private company?
LimFlow SA is a private company. It is classified as corporate owned and is currently acquired.
When was LimFlow SA founded?
LimFlow SA was founded in 2014. It employs 11 to 50 people.
Where is LimFlow SA based?
LimFlow SA is headquartered in Paris, France, in the Europe region.
How does LimFlow SA make money?
Two revenue lines are on record. LimFlow System Device Sales are the primary driver. The others are procedure/Reimbursement Revenue.
Who are LimFlow SA's main competitors?
Broad incumbents on record are Boston Scientific, Medtronic, Terumo (Terumo Interventional Systems), Abbott Vascular, Shockwave Medical (Johnson & Johnson) and Philips (Image-Guided Therapy / Peripheral Vascular). Avinger is listed as an emerging player. Direct peers are Inari Medical (Stryker), Silk Road Medical and Penumbra.
Does LimFlow SA have an API?
No public API is recorded for LimFlow SA.
What industry is LimFlow SA in?
LimFlow SA's product category is Peripheral Vascular Medical Devices. Its primary akta.pro industry code is HLAHAFAJ, Thrombectomy, Embolic Protection & Stroke Intervention Devices. Its NAICS code is 339112 and its SIC code is 3841.